GlassScriptPhysician profile
John M Pagel
NPI 1376633222
$724,564.57
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $234K · 2020: $226K · 2021: $264K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $268,483.98 | 2019-2021 | |
| Kite Pharma, INC. | $128,156.48 | 2019-2021 | |
| Incyte Corporation | $111,359.61 | 2020-2021 | |
| Epizyme, INC. | $41,453.45 | 2020-2021 | |
| Beigene USA, INC. | $41,302.60 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34,296.40 | 2019-2020 | |
| Celgene Corporation | $29,251.63 | 2019-2021 | |
| Astrazeneca Uk Limited | $25,002.50 | 2020-2021 | |
| Verastem, INC. | $13,357.28 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $12,030.00 | 2020-2021 | |
| Eli Lilly and Company | $6,536.50 | 2020-2021 | |
| Seagen INC. | $6,109.76 | 2019 | |
| Morphosys, US INC. | $3,075.00 | 2021 | |
| Gilead Sciences, INC. | $2,700.00 | 2019 | |
| Janssen Biotech, INC. | $843.13 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $525.00 | 2019 | |
| Acerta Pharma LLC | $66.20 | 2019 | |
| Coherus Oncology, INC. | $15.05 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Research and ownership
$1,604.01 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pagel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.